ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 30218
Title: Immunotherapies in sarcoma: Updates and future perspectives
Reviewer’s code: 00723142
Reviewer's country: Oman
Science editor: Jin-Xin Kong
Date sent for review: 2016-09-23 10:40
Date reviewed: 2016-09-23 16:23

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] The same title</td>
<td>[ ] Accept</td>
</tr>
<tr>
<td>[Y] Grade B: Very good</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] High priority for publication</td>
</tr>
<tr>
<td>[ ] Grade C: Good</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Plagiarism</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>[ ] Grade D: Fair</td>
<td></td>
<td>[Y] No</td>
<td>[Y] Minor revision</td>
</tr>
<tr>
<td>[ ] Grade E: Poor</td>
<td></td>
<td></td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

Google Search: [ ]
BPG Search: [ ]

COMMENTS TO AUTHORS
Topic is new and interesting. It is a review of data and trials which need some updating. Some of treatment modalities in STS are not mentioned at all like Trabectedin. A lot of new trials and data is coming out now on this subject. The language need refinement and polishing.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 30218
Title: Immunotherapies in sarcoma: Updates and future perspectives
Reviewer’s code: 00289416
Reviewer’s country: Greece
Science editor: Jin-Xin Kong
Date sent for review: 2016-09-23 10:40
Date reviewed: 2016-10-08 16:31

CLASSIFICATION
[ ] Grade A: Excellent
[ ] Grade B: Very good
[Y] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Poor

LANGUAGE EVALUATION
[ ] Grade A: Priority publishing
[ ] Grade B: Minor language polishing
[Y] Grade C: A great deal of language polishing
[ ] Grade D: Rejected

SCIENTIFIC MISCONDUCT
Google Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[Y] No

BPG Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[Y] No

CONCLUSION
[Y] Accept
[ ] High priority for publication
[ ] Rejection
[ ] Minor revision
[ ] Major revision

COMMENTS TO AUTHORS
The present article represents a review on the current therapeutic aspects of the medical treatment of sarcomas. The authors made a commendable effort and accumulated all the recent phase I and II studies of chemotherapeutic agents, biologocial agents including targeted therapies, with a special effort to delineate current and future immunotherapies that have been used to treat sarcomas of various anatomical sites of the human body. After a brief introduction on the clinicostatistical aspects of these rare and intriguing malignant tumors of mesenchymal origin, the authors give an account of the medical treatment of sarcomas from chemotherapy to targeted therapies. They then give an account on the advances in immune-oncology and the other immunotherapeutic modalities used in the non surgical treatment of sarcomas. After, they give an account on the therapeutic vaccines that have been developed for the various histopathological types of sarcomas as well as the immune inhibitors that these agents affect. They conclude that despite all these efforts and advances in the medical treatment surgery continues to be the treatment of choice for sarcomas of the human body in both the soft tissues and the bone types. Chemotherapy and Immunotherapy are still in an experimental level and Radiotherapy has only an adjuvant role in the treatment of these rare
malignant tumors. The advances in the treatment of melanomas by immunotherapy gives an optimistic account for the better understanding of onco-immunotherapy principles and may result in the improvement of design in future clinical trials. The article is well written, the references current and up to date, and the language acceptable. The present review therefore can be accepted for publication as submitted.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 30218
Title: Immunotherapies in sarcoma: Updates and future perspectives
Reviewer’s code: 00531947
Reviewer’s country: Austria
Science editor: Jin-Xin Kong
Date sent for review: 2016-09-23 10:40
Date reviewed: 2016-10-02 22:32

CLASSIFICATION

[ ] Grade A: Excellent
[ ] Grade B: Very good
[ Y] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Poor

LANGUAGE EVALUATION

[ ] Grade A: Priority publishing
[ Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing
[ ] Grade D: Rejected

SCIENTIFIC MISCONDUCT

Google Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[ Y] No

BPG Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
[ Y] No

CONCLUSION

[ ] Accept
[ ] High priority for publication
[ ] Rejection
[ ] Minor revision
[ Y] Major revision

COMMENTS TO AUTHORS

The short review on immunotherapies in sarcoma was interesting to read, please find my remarks below. 1. Introduction, “Unfortunately, adjuvant chemotherapy is of little benefit except for…” osteosarcoma is missing, as well as trabectedin for myxoid liposarcomas. Please add “neo-/adjuvant” – as chemo for bone sarcomas is pre- and postop in nearly all cases 2. Please discuss the controversies on Mifamurtide. 3. Please check the most recent publications on this topic (2016)